ABSTRACT
Adipose tissue is an abundant, easily accessible, and reproducible cell source for musculo-skeletal regenerative medicine applications. Initial derivation steps yield a heterogeneous population of cells of stromal vascular fraction (SVF) cells.
Subsequent adherent selection of the SVF results in a relatively homogeneous population of adipose-derived stromal/stem cells (ASCs) capable of adipogenic, chondrogenic, myogenic, and osteogenic differentiation in vitro on scaffolds in bioreactors and in vivo in pre-clinical animal models. Unlike hematopoietic cells, ASCs do not elicit a robust lymphocyte reaction and instead release immunosuppressive factors, such as prostaglandin E2. These immunomodulatory features suggest that allogeneic and autologous ASCs will engraft successfully for tissue regeneration purposes. The differentiation and expansion potential of ASCs can be modified by growth factors, bioinductive scaffolds, and bioreactors providing environmental control and biophysical stimulation. Gene therapy approaches using lentiviral transduction can be used to direct differentiation of ASCs to particular lineages. We discuss the utility of ASCs for musculo-skeletal tissue repair and some of the technologies that can be implemented to unlock the full regenerative potential of these highly valuable cells.
INTRODUCTION
Tissue engineering is an emerging field that integrates advances in the fields of biomaterials, cytokines/growth factors, and stem cell biology towards repair and regeneration of damaged tissues and organs. Musculo-skeletal defects due to acute trauma, congenital malformations, degenerative diseases, and neoplasia are potential targets for cell-based regenerative therapies. While scaffolds can be manufactured from either native or synthetic biomaterials, and regulatory signals (molecular and physical) can be provided using advanced bioreactors, large scale production of stem cells and the definition of environmental conditions necessary for these cells to drive the repair processes continue to present major challenges. Stem cells are living biological products whose production requires quality controls for contaminating infectious agents, post-cryopreservation functional testing, tumorigenicity, and viability. It is estimated that de novo creation of a single cubic centimeter of bone tissue will require ~7 X 10 7 cells (1), necessitating the derivation of ~ 10 9 stem cells from a single donor to create a construct that is clinically relevant in size.
Adipose tissue has the potential to meet this demand in a highly reproducible manner (2). This review contains information from recent studies surrounding the isolation and characterization of human adipose-derived stem/stromal cells (ASCs) for musculo-skeletal applications, scaffold and bioreactor technologies used for directed differentiation of these cells, and some of the current pre-clinical and clinical trial data.
FEATURES OF STROMAL VASCULAR FRACTION AND ADIPOSE-DERIVED STEM CELLS

Isolation of stromal vascular fraction and adiposederived stem cells: frequency and yield
Subcutaneous adipose tissue is a relatively accessible reservoir for adult stem cell harvest. Plastic surgeons routinely perform >300,000 elective tumescent lipoaspiration procedures on patients in the U.S. each year, yielding liter volumes of subcutaneous adipose tissue. Routinely, this biological material has been discarded; however, new tissue engineering and regenerative medical approaches are being developed to use it as a source of stromal vascular fraction (SVF) cells and adipose-derived stromal/stem cells (ASCs) (3-6). Several companies have begun marketing closed system surgical devices to harvest and process the lipoaspirate intra-operatively (7, 8). The point of care devices are designed to minimize the risk of tissue contamination and to optimize the reproducibility and reliability of the cell product.
Most isolation procedures have the same basic steps (detailed in (9)). First, the contaminating erythrocytes are removed with a phosphate buffered saline rinse. Then, the tissue is digested with collagenase type I (0.075 to 0.1%) for a period of 30 to 90 minutes at 37 o C. Some investigators also include dispase and/or hyaluronidase in their digestion buffer to improve cell recovery. The SVF cells are separated from the mature, lipid-laden adipocytes by centrifugation at speeds of 300 x g (6). The resulting SVF cell pellet consists of a heterogeneous population of endothelial cells, erythrocytes, lymphocytes, macrophages, pericytes, and pre-adipocytes.
A single milliliter of human subcutaneous adipose tissue typically yields between 100,000 to 500,000 nucleated cells (10-13). A nearly identical SVF cell population can be recovered from the bloody fluid collected during the lipoaspiration procedure without the requirement of a collagenase digestion step (13). Flow cytometric analyses have determined that a significant and reproducible percentage of SVF cells express the following hematopoietic surface antigens: CD11b, CD14, CD34, CD45, HLA-AB, and HLA-DR (12, 14).
The SVF cells have been used without further processing for intraoperative tissue engineering procedures. Clinician investigators have reported excellent outcomes using SVF cells for soft tissue reconstruction of breast and facial defects (3, 4, 15).
Despite this, the SVF cells frequently are innoculated onto plastic culture-ware with or without extracellular matrix coating such as collagen or fibronectin (6). Following a period of several hours to several days, the non-adherent cells are removed and the remaining adherent cells are identified as ASCs. Approximately 1 out of 30 SVF cells will adhere to the tissue culture surface and between 10 5 and 10 6 ASCs can be cultured from a single cubic milliliter of human lipoaspirate after 3 to 7 day (12). ASCs have a distinct surface immunophenotype as assessed by flow cytometric analyses. With progressive passage, the majority of ASCs express the stromal markers CD9, CD10, CD29, CD44, CD73, CD90, and CD166 while, with the exception of HLA-AB, the presence of hematopoietic markers declines relative to the original SVF cells (10, 12, 14, 16, 17). Furthermore, ASCs are positive for pericytic markers such as 3G5 and CD146 (18, 19). Several groups have begun to use combinations of surface proteins as "immune-tags" with which to enrich or isolate ASCs from the SVF cells directly (20). This has been effective in pre-clinical studies but it has yet to be determined if such approaches will prove to be sufficiently robust and cost-efficient for future clinical applications. At present, adhesion to plastic or matrix substrate remains the most common method for direct isolation of ASCs from large volumes of human lipoaspirate. The ASCs are capable of releasing a range of cytokines and growth factors, having significant paracrine effects (21-24).
Furthermore, the ASCs exhibit multipotent differentiation potential in vitro and in vivo (5, 6, 25). Since these features have been covered in several excellent reviews (5, 6, 25), we focus only on those pathways most directly related to musculo-skeletal repair -Chondrogenic, Osteogenic, and Skeletal Myogenic differentiation.
Advantages and limitations relative to amnion, bone marrow, and placental derived stem cells
Human subcutaneous adipose tissue offers several advantages as a stromal/stem cell source. First, with the widespread incidence of obesity, most adult subjects have abundant adipose tissue. Second, the tissue is accessible via a relatively non-invasive harvest technique. The procedure is well accepted by the public as evidenced by the fact that hundreds of thousands of individuals incur significant costs to undergo elective liposuction procedures each year. This is a sharp contrast to the harvest of bone marrow-derived mesenchymal stromal/stem cells (BMSCs) by bone marrow aspiration, a painful procedure that is associated with significant donor site morbidity. Third, the frequency of stromal/stem cells per unit volume of adipose tissue, which are 10-100 times more abundant per unit volume than bone marrow (12), combined with the liter volumes of adipose tissue available makes the isolation and expansion of billions of ASCs within a minimal time frame feasible.
Despite these advantages, there are reported limitations to ASC use. First and foremost, human ASCs maintained in culture for extended periods of time (>3 months) cause sarcomas in immunodeficient mice (26). This underscores the risks of ex vivo stromal/stem cell manipulation and supports the need for minimal cell handling.
Second, a number of investigations have compared ASCs and BMSCs side by side. While some investigators have concluded that they function equally well with respect to chondrogenic and osteogenic differentiation, others have concluded that BMSCs show some superior qualities with respect to differentiation potential (27-33). While it should be noted that these studies have used inductive conditions optimized for the 
3. Chondrogenic potential
Chondrogenic differentiation can be induced in ASCs in vitro by exposure to combination of factors such as dexamethasone, transforming growth factor (TGF) beta 1 or beta 3, and bone morphogenetic protein 6 (BMP6) (16, 42-46) ( Table 1) .
Positive Alcian Blue staining or Safranin O staining confirms chondrogenesis within a 2 to 4 week period (16, 42, 43). Differentiation is most robust in 3-dimensional, as compared to 2-dimensional, culture conditions as determined by expression and synthesis of proteoglycans and chondrocyte-specific genes and proteins. A variety of 3 dimensional approaches have been employed (47-49). The simplest is the use of micromass cultures, where 2.5-5 X 10 5 ASCs are pelleted by centrifugation and maintained for up to 3 weeks under chondrogenic culture conditions (49). At the next level, ASCs are suspended at concentrations of 4 to 10 X 10 6 per ml in gels of alginate, agarose, or gelatin followed by chondrogenic induction (42, 47, 48). As a third alternative, ASCs are seeded onto porous solid scaffolds constructed from collagen, elastin, synthetic materials (polyvinylpropinate, polyglycolic/lactic acid), or cartilage extracellular matrix extracts (50). The chondrogenic potential of ASCs increases with extended passage in vitro; cells at passage 9 exhibited more robust expression of differentiation markers compared to passage 4 (51).
Furthermore, the ASC's culture expansion conditions in monolayer prior to culture in a 3-dimensional or micromass condition influences their chondrogenic potential (52).
Osteogenic potential
ASCs can be induced to undergo osteogenic differentiation in vitro by exposure to a combination of ascorbate, β glycerophosphate, various BMPs, dexamethasone, and/or vitamin D 3 (16, 43, 53, 54) ( Table 2 ). Within a 2 to 4 week period, matrix mineralization is evident based on positive Alizarin Red or von Kossa's staining (16, 43, 53, 54). This mineral formation is accompanied by increased expression of osteogenic proteins and mRNAs, including alkaline phosphatase, bone morphogenetic proteins and their receptors, bone sialoprotein, Cbfa1/Runx2, and osteocalcin (16, 43, 53, 54). Osteoinductive or osteoconductive matrices have been found to further enhance the ASC expression of such markers (please see Section G below). In vitro, the osteogenic capacity of ASCs on scaffolds can be enhanced using a perfusion bioreactor (55). When combined with tricalcium phosphate/hydroxyapaptite matrices, human ASCs form osteoid-like structures when implanted subcutaneously in immunodeficient mice (56, 57). Furthermore, murine ASCs exposed to BMP2 and retinoic acid can repair critical sized craniofacial defects in syngeneic animals; however, the repair process is time dependent (58, 59). After extended periods of time, osteoclast cells infiltrate and resorb the newly formed bone (58, 59). Further studies are required to understand the underlying mechanism for these observations. Clinical trials have begun using ASCs for craniofacial defect repair. The REGEA Institute and Helsinki University Central Hospital in Finland reported the successful repair of a hard palate defect in a 65 year old patient (60). In successive procedures, subcutaneous autologous ASCs were harvested, expanded in culture over 3 weeks, and seeded onto tricalcium phosphate matrices in the presence of BMP2 (60). The cell product was placed within a titanium cage designed in the shape of the patient's defect and implanted into the patient's rectus abdominus muscle (60). After bone formation was confirmed by radiograph after 6-8 months, the construct was harvested and re-implanted into the defect site. Blood supply was re-established by anastomosis with the facial artery (60). The construct completely integrated and the patient had full recovery of function (60). The REGEA group has treated ~20 subjects to date with >90% successful outcomes based on integration of the bone based on radiographic analyses and reconstruction of dentition (personal report, Riita Suuronen, Susanna Miettinen). Similar success in weight bearing bones with autologous or allogeneic human ASCs will significantly advance treatment of orthopedic injuries.
Skeletal muscle potential
ASCs can be induced to express biochemical features consistent with skeletal myogenesis by exposure to low serum conditions and/or horse serum (16, 43, 61-63) (Table 3) . In response to these factors, ASCs express mRNAs encoding myogenic proteins, including the transcriptional regulators MyoD and myogenin as well as structural proteins such as myosin heavy chain (16, 43, 61-63). Based on histological evidence, ASCs fuse to form multinucleated myotubes in vitro. To date, pre-clinical animal and clinical trials using human ASCs for skeletal muscle myogenesis have not been reported. In contrast, there is significant and growing interest worldwide in using ASCs for cardiac myogenesis (64-69). These studies have been included in previous reviews (6, 70, 71) . A comparison of the biomarkers used to distinguish the musculoskeletal differentiation of ASCs is presented in Table 4 .
Immunogenic features -autologous vs allogeneic transplantation
As noted above, the immunophenotype of adipose-derived cells alters as a function of their adherence to tissue culture plastics and passage in vitro. In contrast to SVF cells, passage 2 and greater ASCs lose their expression of HLA-DR and CD86 which serve as recognition markers for T cells (14). While SVF cells elicit a robust mixed lymphocyte reaction from allogeneic peripheral blood monocytes, passaged ASCs are relatively non-reactive (14, 72). Furthermore, the presence of ASCs suppresses on-going mixed lymphocyte reactions between allogeneic peripheral blood monocytes (14, 72). The immunosuppressive properties of ASCs are due, in part, to their production of prostaglandin E 2 and indoleamine 2,3-dioxygenase (73, 74) . In a variety of disease models, ASCs have been found to suppress inflammatory cytokine expression by T cells and to reduce Th1/Th17 cell expansion (75) (76) (77) (78) (79) . The presence of ASCs also stimulated the expression of interleukin 10, an anti-inflammatory cytokine (75) (76) (77) (78) . These ASC immunomodulatory features are similar to those described in BMSCs (80) (81) (82) (83) (84) . In fact, (85, 86) . These early findings have significant implications with respect to the manufacture and quality control of a clinical ASC product that has yet to be tested in clinical trials.
Tissue engineering by using ASCs, 3D scaffolds and perfusion bioreactors
Tissue engineering (TE) methods are being increasingly adopted for translating the multi-lineage potential of ASCs into therapeutic applications. In general, tissue engineering outcomes depend on the ability to predictably guide the ASC assembly into functional differentiated tissues, which in turn requires the combined application of biological, structural and mechanical cues enabling cell differentiation and patterning. Within the body, developmental and regenerative processes are orchestrated by cascades of physiological factors, which vary in space and time, yet are acting in concert to elicit coordinated cellular responses. To recapitulate some of these regulatory cascades in vitro, a 'biomimetic' approach has been established (87) that attempts to recapitulate in vitro (using engineering tools) the native cell/tissue milieu (present during tissue development and remodeling). In an ideal case, the cellular niche is tightly regulated to mimic the native environment of a specific tissue, thereby prompting the cells (individually and collectively) to exhibit differentiated phenotypes unique to that tissue.
In a tissue engineering system, a threedimensional (3D) scaffold provides a structural and logistic template for cell attachment and tissue formation, and a bioreactor provides adequate nutrient transfer and imparts biophysical stimuli to the cultured cells (Figure 1) . The substrate properties and bioreactor conditions are directed by biological requirements, and chosen to closely mimic the native environment of the specific tissue that is being regenerated. For example, hydrogels are frequently chosen to induce chondrogenic responses as they enable the cells to adopt spherical morphologies and facilitate the distribution of compressive stresses that might be applied to the construct. In contrast, osteogenic outcomes are favored by using rigid, porous scaffolds as this structure is reflective of native bone. A recent article reviews distinct techniques that have been utilized for a number of musculo-skeletal tissues with different starting cell populations (87) . Here, we review the use of scaffolds and bioreactors as they have been applied specifically to ASCs. 3D substrates are designed to have specific biochemical, topographical and mechanical properties, to direct the cells to spatially organize, to form functional contacts with other cells and the matrix, and to secrete and assemble tissue-specific extracellular matrix (ECM) when provided with the appropriate lineage-specific stimuli. Various groups have combined ASCs with 3D gels or solid scaffolds to form bone-(88-91), cartilage-(92, 93) and fatlike (94) (95) (96) 
tissues in vitro and in vivo.
The biochemical characteristics of the scaffold stimulate the developing ASCs and, together with soluble growth factors, impart lineage-specific information. It has been shown that ASCs implanted in hydroxyapatitetricalcium phosphate (HA-TCP) scaffolds enabled osteogenic differentiation with far greater efficiency (80 %) than the same cells seeded in Collagraft TM scaffolds (20%) when both scaffolds were implanted subcutaneously into SCID mice and allowed to develop for 6 weeks (88) . The mineral component of the HA-TCP scaffold (and possibly, the increased stiffness relative to Collagraft TM ) appeared to favor an osteogenic phenotype in ASCs. Likewise, increases in the osteogenic differentiation of human ASCs were observed when cells were cultured on different ceramics -akermite vs. β-TCP scaffolds -under otherwise similar in vitro conditions (89) . The akermite scaffolds contained calcium (Ca), magnesium (Mg), and silicone (Si) ions on the surface, which are capable of dissolving into the culture medium and affect the degradation profile of the biomaterial. Other studies, not involving ASCs, have demonstrated that the surface topography and mechanical properties of the scaffolds also influence cellular characteristics and may be equally important in guiding cellular differentiation and determining functional outcomes in orthopaedic applications (97) (98) (99) . Knowledge gleaned from these studies may enable the functional characteristics of the scaffolds to be determined a priori so that their properties can be tailored suit specific outcomes.
A major technical hurdle preventing the immediate clinical translation of tissue-engineered constructs has been their small size. Due to the diffusion limitations of nutrients and metabolic products, only relatively thin layers of viable tissue can be grown under static conditions. Bioreactors are employed to improve nutrient distribution and facilitate the development of homogenous tissues (100). The method for inducing convective flow and specific biophysical stimuli should correlate with the functional characteristics of the tissue being engineered. In vivo, cartilage tissues are exposed to dynamic compressive stimuli (101, 102) , bone constructs (103) and blood vessels (104) require pressure and shear stresses for proper development, tendons and ligaments respond to tensile and shear stresses (105, 106) , and myocardial tissues utilize electrical (107) and contractile (108) stimuli. These stresses, in addition to eliciting cellspecific responses, improve the convective mass transport parameters governing the exchange of nutrients and waste occurring at the inner regions of constructs.
The application of such biophysical forces in bioreactors can be coupled with soluble growth factors as to induce lineagespecific stem cell differentiation and assembly into functional tissues.
Relatively few studies have been published thus far with ASCs cultured on scaffolds in bioreactors. In contrast, multiple studies performed with bone marrowderived stem cells have validated the utility of bioreactor systems as a means of improving cell growth in bone (103, (109) (110) (111) , cartilage (112) and ligament (105) constructs. Yet, two relatively recent studies investigating in vitro bone formation by ASCs in bioreactor configurations have been particularly instructive.
In the first study, Scherberich et al (113) employed bioreactor cultivation as a means to avoid conventional monolayer cultivation and better preserve the native multi-lineage capabilities of ASCs. The stromal vascular fraction (SVF) cells were seeded directly into hydroxyapatite scaffolds and cultured for 5 days in a perfusion bioreactor prior to implanting subcutaneously into nude mice. The osteogenic and vascular components within these constructs were assessed after 8 weeks of subcutaneous cultivation. In parallel, SVF cells were culture-expanded for 5 days using traditional monolayer methods prior to implantation into the hydroxyapatite scaffolds. These constructs were also implanted into nude mice and assessed after 8 weeks. , but only constructs grown in the bioreactors exhibited bone formation. Within the same study, SVF cells seeded directly into scaffolds and implanted without bioreactor cultivation also failed to form bone. This suggests that the osteogenic capabilities were not lost during monolayer expansion, but that the effects of the scaffold biochemistry and bioreactor cultivation were somehow combined to prime the cells along an osteogenic lineage.
A more recent study offers insights into the 'priming' of ASCs in vitro by their cultivation on osteogenic scaffolds in a bioreactor with medium perfusion, to obtain thick bone constructs (Figure 2) (114) . ASCs at the 3 rd passage were seeded into 4 mm thick scaffolds made of decellularized trabecular bone, at a high initial density, and cultivated either in perfusion bioreactors or in static conditions for 5 weeks to evaluate the in vitro boneforming properties of ASCs.
The same osteogenic supplements (dexamethasone, beta-glycerophosphate and ascorbic acid) were used under both cultivation conditions. Medium flow through the interstitial pore spaces of the seeded constructs significantly enhanced ASC viability and tissue uniformity relative to constructs cultured without perfusion (Figure 2) . It was postulated that the improved cell-cell contacts, in particular within the central region of the constructs, resulted in improved collagen matrix deposition and expression of bone-specific proteins (bone sialoprotein and osteopontin). This study further supports scientific advantages of using bioreactor systems providing environmental control and biophysical signaling for directed differentiation of stem cells in general and ASCs in particular. The related manufacturing and regulatory issues that need to be considered to make this technology clinically viable are being addressed in current studies (115, 116) .
Combination with gene transduction vectors
Human ASCs can be transduced with a variety of viral vectors to express specific genes of interest (117, 118) . Comparative analyses have determined that lentiviral vectors infect ASCs more efficiently than adenoviral or retroviral vectors (117) .
Bone formation has been enhanced in rat models by ASC delivery vehicle of BMP2 as a virally expressed protein (118) . Similarly, human ASCs with a lentiviral expression vector for MyoD displayed improved myogenic potential in a murine model of muscular dystrophy (119) .
Recently, human ASCs have been transduced with lentiviral vectors expressing four transcription factors (c-myc, klf4, oct-4, sox2) to create induced pluripotent stem (iPS) cells (120) . Human ASC derived iPS cells express surface markers comparable to embryonic stem cells, displayed pluripotent differentiation potential in vitro, and form teratomas following in vivo implantation (120) . The frequency of iPS cell induction is low, but pluripotent cell lines derived 
PERSPECTIVE AND CONCLUSIONS
Human ASCs offer major practical and theoretical advantages for future tissue engineering and regenerative medical applications, with several challenges that are being addressed in ongoing studies. The abundance, accessibility, reproducibility, and ease of isolation of ASCs are among the major reasons for using ASCs in musculo-skeletal repair. While some studies have raised concerns about the inferiority of ASCs relative to BMSCs with respect to chondrogenic or osteogenic differentiation in vitro, it should be noted that such studies were conducted using osteoinductive conditions that were optimized for BMSCs. Work by Estes (45), Henning (44), and their colleagues has demonstrated that appropriate combinations of growth factors, different from those routinely used for BMSCs, are necessary to augment chondrogenic capacity of ASCs. Similar approaches, using growth factors and/or scaffolds, have the potential to further improve the myogenic and osteogenic differentiation of ASCs. Over the past decade, human ASC research has progressed from its focus on in vitro and preclinical animal models to human clinical trials. The next decade is likely to yield definitive studies supporting the safety and efficacy of using ASCs for bone, cartilage, and muscle repair. Such outcomes will most likely enhance our ability to treat disabilities that routinely impair quality of life for patients of all ages.
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